FILTER
FILTERED INTERVIEW RESULTS
George Arhin
PARTNER AND PWC WEST AFRICA MINING LEADER
"This is the best time for mining companies to invest in cost optimization solutions to sustain their business when the gold prices dip."
Stéphane Rabut
GLOBAL EXPLOSIVES DIRECTOR, TITANOBEL
"Africa remains our primary focus, providing many opportunities driven by a vibrant mining industry, as well as less competition and the possibility of attaining a larger market share."
Doris Afanyedey
GENERAL MANAGER, CUMMINS GHANA
"The mining sector across West Africa is ripe with opportunities and we are looking to expand our network of dealers."
Tom Palmer
PRESIDENT AND CEO, NEWMONT
Tom Palmer discussed Newmont’s global operations, investments and ESG strategy.
Ivan Doku
PRINCIPAL RESOURCE GEOLOGIST AND GHANA COUNTRY MANAGER, SRK CONSULTING
"Buoyant commodity prices have certainly boosted the mining sector in West Africa, leading to better demand for technical studies, audits, reviews and other work that SRK offers."
Douglas MacQuarrie
PRESIDENT & CEO, ASANTE GOLD
"We are helped by the high gold prices and a market keen to provide the needed capital to wake up this sleeping giant."
Dolores Biamou
MINING PROJECTS DIRECTOR AFRICA, BOLLORÉ LOGISTICS
Bolloré Logistics explains how it has been able to maintain the supply chain for mines in Africa despite the pandemic and security threats.
Laurent Piat
MANAGING DIRECTOR, VEOLIA GHANA
Veolia designs and provides solutions for water, waste and energy management.
Bernard Kaninda
REGIONAL DIRECTOR AFRICA, MAXAM
Maxam describes its services and the current opportunities in West Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
